// App-Quantinova.ai

7041 : A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia (ALL): Updated results.

Researchers

Presenter

  • Abdul Hamid Bazarbachi

Principal Investigators

  • Farhad Ravandi

  • Deborah A. Thomas

  • Maria Khouri

  • Guillermo Garcia-Manero

  • Rebecca S. Garris

  • Jorge E. Cortes

  • Nicholas James Short

  • Koji Sasaki

  • Ghayas C. Issa

  • Paul B. Koller

  • Tapan M. Kadia

  • Srdan Verstovsek

  • Naval Guastad Daver

  • Nitin Jain

  • Marina Konopleva

  • Susan Mary O'Brien

  • Elias Jabbour

  • Hagop M. Kantarjian

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Baylor College of Medicine, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Houston, TX

  • The University of Texas MD Anderson Cancer Center, Leukemia Department, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • University of California, Irvine, Fullerton, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • N/A

Biomarkers

  • B-lymphocyte antigen CD20

  • Breakpoint Cluster Region

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Methotrexate

  • Asparaginase

  • Vincristine

  • Doxorubicin

  • Cytarabine liposomal

  • ofatumumab Intravenous

  • ara-c

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01363128

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved